HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767 | Completed Phase 1 FDA Drug

• 1 other identifier: 2022-523-00US2
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Conditions

Relapsed or Refractory Lymphoma

Outcome Measures

Primary Outcomes (3)

• PK parameter for HMPL-523: AUC0-t

  Area under the plasma concentration-time curve from time 0 to time of the last measurable concentration

  Day 1 to 18

• PK parameter for HMPL-523: AUC0-inf

  Area under the plasma concentration-time curve from time 0 extrapolated to infinity (if data permit)

  Day 1 to 18

• PK parameter for HMPL-523: Cmax

  Maximum observed plasma concentration

  Day 1 to 18

Secondary Outcomes (1)

• Incidence of Adverse Events/ Serious Adverse Events

  Day 1 to Day 18

Study Arms (2)

Part A - Itraconazole

EXPERIMENTAL

HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 400 mg (combination of 2 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 10) in Part A. Itraconazole will be supplied as 100 mg capsules and will be administered as doses of 200 mg (2 × 100 mg) PO BID on Day 6 and 200 mg PO QD on Days 7 to 14 in Part A.

Drug: HMPL-523; Drug: Itraconazole

Part B - Rifampin

EXPERIMENTAL

HMPL-523 will be supplied as 100 and 150 mg tablets and will be administered PO as a single dose of 700 mg (combination of 4 of 150 mg tablets and 1 of 100 mg tablet) on two separate occasions (Day 1 and Day 13) in Part B. Rifampin will be supplied as 300 mg capsules and will be administered as doses of 600 mg (2 × 300 mg) PO QD on Days 6 to 17 in Part B.

Drug: HMPL-523; Drug: Rifampin

Interventions

HMPL-523 DRUG

HMPL-523 is a selective small-molecule SYK inhibitor.

Part A - Itraconazole; Part B - Rifampin

Itraconazole DRUG

Itraconazole is an FDA approved synthetic triazole antifungal agent

Part A - Itraconazole

Rifampin DRUG

Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state

Part B - Rifampin

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• \. The volunteer is male or female between the ages of 18 and 55 years old (inclusive) at the time of informed consent.
• \. The volunteer has a body mass index (BMI) \>18 and ≤29.9 kg/m2 at screening.
• \. Females must be postmenopausal (defined as absence of menses for at least one year without alternative medical cause) or permanently sterile by total hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
• \. Males, including those who have had a successful vasectomy, must use a condom during sexual intercourse with women of childbearing potential, starting from their first dose of study drug through 30 days after their last dose of study drug. Alternatively, abstinence is allowed if it is the normal and preferred lifestyle of the volunteer.
• \. The volunteer must provide written informed consent prior to any study specific screening procedures.
• \. The volunteer is willing and able to comply with all aspects of the protocol, as determined by the PI.
• \. The volunteer must have normal laboratory results for total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT); creatinine clearance must be \> 90 mL/min estimated using the Cockcroft-Gault equation.

You may not qualify if:

• \. The volunteer has a known history of any gastrointestinal surgery or any condition possibly affecting drug absorption (eg, cholecystectomy, gastrectomy, achlorhydria, peptic ulcer disease, or history of stomach or intestinal surgery or resection).
• Note: Appendectomy and hernia repairs are allowed.
• \. The volunteer had a clinically significant illness within 8 weeks or a clinically significant infection within 4 weeks prior to the first dose.
• \. The volunteer has evidence of a clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations at screening or at Day -1 check-in (baseline).
• \. The volunteer has systolic blood pressure \>140 mmHg or a diastolic blood pressure \>90 mmHg.
• \. The volunteer has a clinically significant ECG abnormality, including a marked baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTcF interval \>450 msec), or had a family history of prolonged QTc syndrome or sudden death.
• \. The volunteer has a history of smoking or use of nicotine-containing substances within the previous 2 months, as determined by medical history or volunteer's verbal report and confirmed by cotinine test at check-in for each treatment period.
• \. The volunteer has a history of drug or alcohol misuse within 6 months prior to screening or a positive urine drug test at screening or at check-in for each treatment period.
• \. The volunteer has been diagnosed with acquired immune deficiency syndrome or has performed tests that are positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
• \. The volunteer has participated in a clinical trial of another study drug before screening, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks, whichever is longer, or the volunteer is currently enrolled in another clinical trial.
• \. The volunteer has consumed grapefruit, starfruit, Seville oranges, or their products within 7 days prior to the first dose.
• \. The volunteer has consumed herbal preparations/medications, including, but not limited to, St. John's Wort, kava, ephedra (ma huang), Ginkgo biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng, within 7 days prior to the first dose (21 days for St. John's Wort).
• \. The volunteer has experienced a weight loss or gain of \>10% within 4 weeks prior to the first dose as noted by medical history and weight at screening and check-in.
• \. The volunteer has received blood or blood products within 4 weeks, donated blood or blood products within 8 weeks prior to the first dose or donated double red cell within 16 weeks prior to first dose.
• \. The volunteer has used any over-the-counter (OTC) medications or prescription drugs (including medications that can lower gastric acid, inhibit or induce P-gp and/or CYP3A4) within 5 half-lives of these drugs or 2 weeks prior to the first dose of study drug, whichever is longer.

Sponsors & Collaborators

• Hutchmed: lead

Study Sites (1)

PPD Austin

Austin, Texas, 78744, United States

Location

MeSH Terms

Conditions

Recurrence; Lymphoma

Interventions

Itraconazole; Rifampin

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Piperazines; Rifamycins; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Lactams, Macrocyclic; Macrocyclic Compounds; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 31, 2023
• First Posted: February 9, 2023
• Study Start: November 4, 2022
• Primary Completion: February 5, 2023
• Study Completion: February 5, 2023
• Last Updated: March 1, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)